Cargando…

Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs

BACKGROUND: Non-specific immunotherapeutics have been evaluated previously in dogs, primarily for cancer treatment. However, there remains a need for a more broadly targeted, general purpose immunotherapeutic capable of activating innate immune defenses for non-specific protection or early treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheat, William, Chow, Lyndah, Kuzmik, Alana, Soontararak, Sirikul, Kurihara, Jade, Lappin, Michael, Dow, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743184/
https://www.ncbi.nlm.nih.gov/pubmed/31519215
http://dx.doi.org/10.1186/s12917-019-2073-8
_version_ 1783451235690479616
author Wheat, William
Chow, Lyndah
Kuzmik, Alana
Soontararak, Sirikul
Kurihara, Jade
Lappin, Michael
Dow, Steven
author_facet Wheat, William
Chow, Lyndah
Kuzmik, Alana
Soontararak, Sirikul
Kurihara, Jade
Lappin, Michael
Dow, Steven
author_sort Wheat, William
collection PubMed
description BACKGROUND: Non-specific immunotherapeutics have been evaluated previously in dogs, primarily for cancer treatment. However, there remains a need for a more broadly targeted, general purpose immunotherapeutic capable of activating innate immune defenses for non-specific protection or early treatment of viral and bacterial infections. To address need, our group has developed a liposomal immune stimulant (liposome-TLR complexes, LTC) containing TLR 3 and 9 agonists specifically designed to activate mucosal immune defenses in sites such as nasal cavity and oropharynx, following topical delivery. In this study, we evaluated the local immune stimulatory properties of LTC in vitro and in healthy purpose-bred dogs, including activation of cellular recruitment and cytokine production. The ability of LTC treatment to elicit effective antiviral immunity was assessed in dogs following a canine herpesvirus outbreak, and the impact of LTC treatment on the local microbiome of the oropharynx was also investigated. RESULTS: These studies revealed that LTC potently activated innate immune responses in vitro and triggered significant recruitment of inflammatory monocytes and T cells into the nasal cavity and oropharynx of healthy dogs. Administration of LTC to dogs shortly after an outbreak of canine herpesvirus infection resulted in significant reduction in clinical signs of infection. Interestingly, administration of LTC to healthy dogs did not disrupt the microbiome in the oropharynx, suggesting resiliency of the microflora to transient immune activation. CONCLUSIONS: Taken together, these results indicate that LTC administration mucosally to dogs can trigger local innate immune activation and activation of antiviral immunity, without significantly disrupting the composition of the local microbiome. Thus, the LTC immune stimulant has potential for use as a non-specific immunotherapy for prevention or early treatment of viral and bacterial infections in dogs.
format Online
Article
Text
id pubmed-6743184
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67431842019-09-16 Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs Wheat, William Chow, Lyndah Kuzmik, Alana Soontararak, Sirikul Kurihara, Jade Lappin, Michael Dow, Steven BMC Vet Res Research Article BACKGROUND: Non-specific immunotherapeutics have been evaluated previously in dogs, primarily for cancer treatment. However, there remains a need for a more broadly targeted, general purpose immunotherapeutic capable of activating innate immune defenses for non-specific protection or early treatment of viral and bacterial infections. To address need, our group has developed a liposomal immune stimulant (liposome-TLR complexes, LTC) containing TLR 3 and 9 agonists specifically designed to activate mucosal immune defenses in sites such as nasal cavity and oropharynx, following topical delivery. In this study, we evaluated the local immune stimulatory properties of LTC in vitro and in healthy purpose-bred dogs, including activation of cellular recruitment and cytokine production. The ability of LTC treatment to elicit effective antiviral immunity was assessed in dogs following a canine herpesvirus outbreak, and the impact of LTC treatment on the local microbiome of the oropharynx was also investigated. RESULTS: These studies revealed that LTC potently activated innate immune responses in vitro and triggered significant recruitment of inflammatory monocytes and T cells into the nasal cavity and oropharynx of healthy dogs. Administration of LTC to dogs shortly after an outbreak of canine herpesvirus infection resulted in significant reduction in clinical signs of infection. Interestingly, administration of LTC to healthy dogs did not disrupt the microbiome in the oropharynx, suggesting resiliency of the microflora to transient immune activation. CONCLUSIONS: Taken together, these results indicate that LTC administration mucosally to dogs can trigger local innate immune activation and activation of antiviral immunity, without significantly disrupting the composition of the local microbiome. Thus, the LTC immune stimulant has potential for use as a non-specific immunotherapy for prevention or early treatment of viral and bacterial infections in dogs. BioMed Central 2019-09-13 /pmc/articles/PMC6743184/ /pubmed/31519215 http://dx.doi.org/10.1186/s12917-019-2073-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wheat, William
Chow, Lyndah
Kuzmik, Alana
Soontararak, Sirikul
Kurihara, Jade
Lappin, Michael
Dow, Steven
Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs
title Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs
title_full Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs
title_fullStr Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs
title_full_unstemmed Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs
title_short Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs
title_sort local immune and microbiological responses to mucosal administration of a liposome-tlr agonist immunotherapeutic in dogs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743184/
https://www.ncbi.nlm.nih.gov/pubmed/31519215
http://dx.doi.org/10.1186/s12917-019-2073-8
work_keys_str_mv AT wheatwilliam localimmuneandmicrobiologicalresponsestomucosaladministrationofaliposometlragonistimmunotherapeuticindogs
AT chowlyndah localimmuneandmicrobiologicalresponsestomucosaladministrationofaliposometlragonistimmunotherapeuticindogs
AT kuzmikalana localimmuneandmicrobiologicalresponsestomucosaladministrationofaliposometlragonistimmunotherapeuticindogs
AT soontararaksirikul localimmuneandmicrobiologicalresponsestomucosaladministrationofaliposometlragonistimmunotherapeuticindogs
AT kuriharajade localimmuneandmicrobiologicalresponsestomucosaladministrationofaliposometlragonistimmunotherapeuticindogs
AT lappinmichael localimmuneandmicrobiologicalresponsestomucosaladministrationofaliposometlragonistimmunotherapeuticindogs
AT dowsteven localimmuneandmicrobiologicalresponsestomucosaladministrationofaliposometlragonistimmunotherapeuticindogs